Rachel Koldej

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C Tebbutt, Michael Michael, Emma Link, Stephen Q Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J Solomon, Grant A McArthur, Rodney J Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai

Journal article  |  2023  |  Clin Cancer Res

PURPOSE: BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches bei..

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma.

undefined Jake Shortt, Peter Galettis, Chan Y Cheah, Joanne Davis, Mandy Ludford-Menting, Emma K Link, Jennifer H Martin, Rachel Koldej, David Ritchie

Journal article  |  2023  |  Clin Epigenetics

BACKGROUND: N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applicati..

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Westerman, Ing S Tiong, Adam Ivey, Piers Blombery, Natasha S Anstee, Rachel M Koldej, David J Curtis, David Kipp, David Ritchie, David M Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn Grove, Paula Marlton, et al.

Journal article  |  2022  |  Blood

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Chong Chyn Chua, Natasha S Anstee, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Rachel M Koldej, Stephen B Ting, Travis Perera, Amanda Johnston, John Reynolds, David Ritchie, Andrew H Wei

Journal article  |  2022  |  Blood

Immunologic Basis to Poor Graft Function Following Allogeneic Stem Cell Transplantation

Ashvind Anand Prabahran, Rachel M Koldej, Lynette CY Chee, David Ritchie

Journal article  |  2022  |  Blood

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Adrian Minson, Nada Hamad, Chan Y Cheah, Constantine S Tam, Piers Blombery, David A Westerman, Stephen Lade, David Ritchie, Rachel M Koldej, Mary Ann Anderson, Amit Khot, John F Seymour, Molly Robertson, Imogen R Caldwell, Georgina L Ryland, Jing Xie, Huw Morgan, Michael Dickinson

Journal article  |  2022  |  Blood

Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review

Ashvind Prabahran, Rachel Koldej, Lynette Chee, Jeff Szer, David Ritchie

Journal article  |  2022  |  BONE MARROW TRANSPLANTATION

The development of non-relapse cytopenias (NRC) is a relatively common occurrence post allogeneic stem cell transplant (alloSCT). ..

Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation

Ashvind Prabahran, Rachel Koldej, Lynette Chee, David Ritchie

Journal article  |  2022  |  BLOOD ADVANCES

Poor graft function (PGF), defined by the presence of multilineage cytopenias in the presence of 100% donor chimerism, is a seriou..

Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)

Lynette Chee, David Ritchie, Mandy Ludford-Menting, Jane Ripley, Jessica Chung, Daniel Park, Sam Norton, Melita Kenealy, Rachel Koldej

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

OBJECTIVES: Myelodysplastic syndromes (MDS) are characterised by ineffective haematopoiesis. Although hypomethylating agents (HMA)..

P799: SPATIAL ANALYSIS IDENTIFIES A SPECTRUM OF IMMUNE DYSREGULATION IN ACQUIRED BONE MARROW FAILURE CONDITIONS

R Koldej, A Prabahran, CW Tan, M Davis, D Ritchie

Journal article  |  2022  |  HemaSphere